Sutro Biopharma stock hits 52-week low at $2.02 By Investing.com Sutro Biopharma stock hits 52-week low at $2.02…
Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago As every investor would know, not every swing hits the sweet spot. But you have a problem if you face…
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024 SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…
Sutro Biopharma (STRO) Rises 9% in the Past Week: Heres Why Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to…
Coping with a Wild Ride: Investing in Sutro Biopharma (NASDAQ:STRO) Short-term volatility is the hallmark of clinical-stage biopharma investing, and Sutro Biopharma (NASDAQ:STRO) is a fine example of that, recently…
Coping with a Wild Ride: Investing in Sutro Biopharma (NASDAQ:STRO) Short-term volatility is the hallmark of clinical-stage biopharma investing, and Sutro Biopharma (NASDAQ:STRO) is a fine example of that, recently…
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates Sutro Biopharma (STRO) delivered earnings and revenue surprises of 151.22% and 834.90%, respectively, for the quarter ended December 2023. Do…
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains? Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in…